

Magnesium disorders can cause calcium pyrophosphate deposition disease: A case report and literature review

Akanksha Joshi , Chokkalingam Siva 

Abstract

Calcium pyrophosphate deposition (CPPD) disease, also known as pseudogout, is one of the most common forms of inflammatory arthritis. A variety of comorbidities and metabolic conditions have been recognized to predispose to CPPD. We describe here a patient with chronic CPP arthritis due to hypomagnesemia, which is one of the metabolic etiologies associated with CPPD, especially in younger patients. We also performed a literature search and reviewed all reported cases of CPPD disease associated with hypomagnesemia. All cases of hypomagnesemia and its etiologies leading to CPP arthropathy identified in the literature by this systematic search are summarized in this paper.

Keywords: Magnesium, CPPD, pseudogout, calcium pyrophosphate deposition disease, hypomagnesemia, chondrocalcinosis

Introduction

Calcium pyrophosphate deposition (CPPD) disease, also known as pseudogout, is one of the most common forms of inflammatory arthritis. Chondrocalcinosis, defined as the calcification of the cartilage and identified by radiological or histological examinations, is a common feature of CPPD. Calcification of the articular cartilage was reported in the literature as early as the 1920s (1). Zitnan et al. (2) described radiographic chondrocalcinosis associated with joint disease in the 1950s. However, it was not until 1962 that McCarty et al. (3) identified CPPD crystals in the synovial fluid.

Historically, various nomenclatures such as pseudorheumatoid arthritis, pseudoankylosing spondylitis, articular chondrocalcinosis, and pseudogout have been employed to describe CPPD disease (2, 4). In 2011, the European League Against Rheumatism task force redefined the terminology into the subsets of asymptomatic CPPD, osteoarthritis (OA) with CPPD, acute CPP crystal arthritis, and chronic CPP crystal inflammatory arthritis to illustrate the entire spectrum of CPPD disease (5).

A variety of comorbidities and metabolic conditions have been recognized to predispose to CPPD (Table 1). We describe here a patient with chronic CPP arthritis due to hypomagnesemia, which is one of the metabolic etiologies associated with CPPD, especially in younger patients. We also performed a literature search and reviewed all reported cases of CPPD disease associated with hypomagnesemia. We used the following keywords to search the MEDLINE database: (a) "magnesium," (b) "chondrocalcinosis," (c) "CPPD," and (d) "pseudogout." Searching for (b), (c), or (d) produced 1,936 articles, and combining these titles with the keyword "magnesium" resulted in 60 articles. All cases of hypomagnesemia leading to CPP arthritis identified by this systematic search are summarized in Table 2.

Case Presentation

A 32-year-old Caucasian female presented with acute onset of left ankle pain and swelling. Arthrocentesis revealed cloudy yellowish fluid with a white blood cell (WBC) count of 32,300 cells/mm³, red blood cell (RBC) count of 2,100

Table 1. Risk factors associated with CPPD disease

1. Increasing age
2. Known osteoarthritis of the joints
3. Previous joint injury
4. History of knee meniscectomy
5. Metabolic diseases
 - a. Hypomagnesemia
 - b. Hemochromatosis
 - c. Hyperparathyroidism
 - d. Hypophosphatasia

CPPD: calcium pyrophosphate deposition



ORCID IDs of the authors:

A.J. 0000-0002-2230-3761;
C.S. 0000-0002-4546-762X.

Cite this article as: Joshi A, Siva C. Magnesium disorders can cause calcium pyrophosphate deposition disease: A case report and literature review. *Eur J Rheumatol* 2018; 5: 53-7.

Division of Rheumatology, Department of Internal Medicine, University of Missouri, Columbia, MO, USA

Address for Correspondence:
Akanksha Joshi, Division of Rheumatology, Department of Internal Medicine, University of Missouri, Columbia, MO, USA

E-mail: akankshadr@gmail.com

Submitted: 12 December 2016

Accepted: 16 March 2017

Available Online Date: 29 August 2017

©Copyright by 2018 Medical Research and Education Association - Available online at www.eurjrheumatol.org.

Table 2. All cases of CPP arthritis due to hypomagnesemia identified in the literature

Reference	Age/Sex	Primary Diagnosis	Mg Level	Presentation
Hahn et al. (24)	60/M	SBS	0.2 mmol/L	Arthralgias with CC
Whelan et al. (30)	56/M	Thiazide-induced hypomagnesemia	0.48 µg/L	A-CP
Richetite et al. (31)	56/F	SBS	0.56 mmol/L	A-CP
	73/F	SBS and radiation enteritis	0.62 mmol/L	CC, A-NCP
	45/M	SBS	0.41 mmol/L	CC, A-NCP
Hang-Korng et al. (32)	53/M	Gitelman syndrome	0.54 mmol/L	CC, A-NCP
Perez-Ruiz et al. (20)	64/F	Liver transplant for chronic liver disease	1.36 mg/dL	A-CP, CC
	48/F	Liver transplant for chronic liver disease	1.39 mg/dL	A-CP
Melvin et al. (21)	65/F	Hyperparathyroidism	0.8 meq/L	A-NCP, CC
Gonzalez Dominguez et al. (33)	40/M	Hypomagnesemia - unknown cause	1.4 mg/dL	A-NCP, CC
	43/M	Hypomagnesemia - unknown cause	1.6 mg/dL	A-NCP, CC
Waitman et al. (34)	60/M	Bartter syndrome	0.75 mg/dL	A-CP, CC
Milazzo et al. (35)	40/F	Genetic defect of Mg metabolism	0.46 mmol/L	A-CP, CC
Resnick et al. (36)	30/M	Renal dysfunction causing low Mg	0.5 mgm/dL	A-NCP, CC
	52/M	Renal dysfunction causing low Mg	1.8 mg/dL	A-CP, CC
Salvarani et al. (37)	38/M	Bartter syndrome	0.8 mg/dL	A-CP, CC
Bauer et al. (38)	24/M	Bartter syndrome	0.4 mmol/L	CC
	40/F	Bartter syndrome	0.53 mmol/L	CC
De Bruyne et al. (25)	32/M	Bartter syndrome	0.7 meq/L	CC
Goulon et al. (39)	37/F	Bartter syndrome	16 mg/L	CC
	27/M	Bartter syndrome	14 mg/L	CC
Hurault de Ligny et al. (40)	24/F	Bartter syndrome	0.46 mmol/L	CC
Schwarz et al. (41)	32/M	Bartter syndrome	0.29 meq/L	CC
Punzi et al. (42)	54/F	Gitelman syndrome	0.44 mmol/L	A-CP, CC
	27/M	Gitelman syndrome	0.6 mmol/L	A-CP, CC
	35/M	Gitelman syndrome	0.59 mmol/L	CC
	37/F	Gitelman syndrome	0.35 mmol/L	A-CP, CC
Cimbeck et al. (43)	17/M	FHHNC	1.1 mg/dL	A-NCP
Hisakawa et al. (44)	45/F	Bartter syndrome	1.2 meq/L	A-NCP, CC
Mayoux-Beuhamou et al. (45)	26/F	Bartter syndrome	0.55 mmol/L	CC
	56/F	Bartter syndrome	0.35 mmol/L	CC
Dupond et al. (46)	38/F	Bartter syndrome	0.48 mmol/L	CC
De Heide et al. (47)	44/F	Bartter syndrome	0.65 mmol/L	CC
Jones et al. (48)	49/F	Bartter syndrome	0.5 mmol/L	CC
Smilde et al. (49)	39/F	Bartter syndrome	0.56 mmol/L	CC
	56/M	Bartter syndrome	0.60 mmol/L	CC
	59/M	Bartter syndrome	0.60 mmol/L	CC
	41/F	Bartter syndrome	0.49 mmol/L	CC
	37/M	Bartter syndrome	0.54 mmol/L	CC
	43/M	Bartter syndrome	0.49 mmol/L	CC
	44/M	Bartter syndrome	0.52 mmol/L	CC
Munoz-Fernandez et al. (50)	65/M	Bartter syndrome	1.2 mmol/L	CC

A-CP: arthritis-crystal proven; A-NCP: arthritis-non-crystal proven; CC: chondrocalcinosis; SBS: short bowel syndrome; Mg: magnesium

cells/mm³, but no crystals. She underwent irrigation and debridement of the joint and was treated with intravenous antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). Two weeks later, she again presented with acute right knee pain and swelling. Arthrocentesis of the right knee revealed slightly cloudy yellowish synovial fluid with WBC count of 2,400 cells/mm³, RBC count of 400 cells/mm³, and CPP crystals. Radiography of the right knee (Figure 1) revealed significant chondrocalcinosis. Additional investigations were performed to screen for conditions associated with CPPD disease, which revealed low levels of magnesium (Mg) (0.9 mmol/L) and ionized Mg (0.21 mmol/L; normal range: 0.43-0.61 mmol/L). She had normal ferritin, iron saturation, total iron-binding capacity, parathyroid hormone levels, and negative rheumatoid factor and anti-cyclic citrullinated peptide antibodies. C-reactive protein level was elevated at 5.0 mg/dL (normal: 0.0-0.5 mg/dL). Hypomagnesemia-induced CPPD disease was diagnosed, and the patient was given intra-articular steroid injection followed by oral prednisone 10 mg daily, colchi-




Figure 1. Anteroposterior radiograph of the right knee demonstrating radiodense material between the articular surfaces suggesting meniscal calcification

Table 3. Major disorders described in the literature that cause hypomagnesemia with the presence of CPPD disease

1. Gitelman syndrome
2. Bartter syndrome
3. Short bowel syndrome
4. Renal dysfunction leading to magnesium wasting
5. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis
6. Liver transplant for chronic liver disease
7. Thiazide diuretics-induced hypomagnesemia

CPPD: calcium pyrophosphate deposition

cine 0.6 mg twice daily, and hydroxychloroquine 200 mg twice daily. The joint swelling and pain resolved in 6 weeks, and the patient was maintained on hydroxychloroquine and colchicine. Twenty-four-hour urine studies demonstrated low urinary excretion of potassium and calcium and high urinary excretion of Mg at 4.7% (>2% is significant in the setting of hypomagnesemia), indicating Mg wasting. In the setting of these findings and normal blood pressure, a diagnosis of Gitelman syndrome was made. Besides Mg supplements, the patient was also started on amiloride at 5 mg daily, with the dose eventually titrated to 30 mg daily.

Pathogenesis of CPPD Disease

Calcium pyrophosphate crystal formation is principally dependent on the presence of extracellular inorganic pyrophosphate (PPI) mostly produced in the joints by chondrocytes. Extracellular PPI is primarily produced by two mechanisms:

1. Transportation of the intracellular PPI across the chondrocyte membrane by ankylosing protein, a membrane transporter
2. Degradation of ATP into AMP and PPI by nucleoside triphosphate pyrophosphohydrolase ectoenzymes found on the plasma membranes of chondrocytes and on matrix vesicles found in the cartilage matrix

Various factors have been found to modify the production of extracellular PPI by chondrocytes. One of the strongest stimulators of extracellular PPI is the transforming growth factor- β (TGF- β) (6, 7). Intracellular growth factor-1 (IGF-1) antagonistically inhibits the production of extracellular PPI induced by TGF- β (8, 9).

Cartilage intermediate layer protein, which restricts IGF-1 from inhibiting TGF- β , has been found to increase in the cartilage tissue with increasing age (10). Patients with OA may have increased PPI levels due to the insensitivity of chondrocytes to IGF-1, leading to CPPD deposition in the joints damaged with OA (11). PPI is hydrolyzed to inorganic phosphate by alkaline phosphatase (ALP) and inorganic pyrophosphatases. In hypophosphatasia, a congenital condition due to a mutation in *ALPL*, decreased ALP levels lead to excess accumulation of inorganic pyrophosphatases (12). Excess iron in hemochromatosis acts as an inhibitor of ALP, thus leading to excess inorganic pyrophosphatase. Similarly, Mg acts as a cofactor for ALP enzyme, and its deficiency results in excess accumulation of inorganic pyrophosphatase.

Magnesium Disorders

Several conditions causing hypomagnesemia have been attributed in the literature to cause

CPPD disease (Table 3). In Gitelman syndrome, an autosomal recessive disorder, mutations in *SLC12A3*, which encodes for thiazide-sensitive sodium chloride cotransporter in the distal convoluted tubule, lead to urinary Mg wasting, hypomagnesemia, hypokalemia, hypocalciuria, and metabolic alkalosis (13, 14). Patients with Bartter syndrome, an autosomal recessive salt-wasting tubulopathy, characteristically present with hypokalemia, metabolic alkalosis, and secondary hyperaldosteronism with normal to low blood pressure. The Gitelman variant of Bartter syndrome is frequently linked with hypomagnesemia, and it is suggested that most cases of chondrocalcinosis and CPPD disease reported in Bartter syndrome most likely had the Gitelman variant rather than Bartter syndrome per se (15, 16). Hypomagnesemia occurs in short bowel syndrome (SBS) through various mechanisms. Bacterial fermentation of carbohydrates and high intake of dietary fat can increase the concentration of fatty acids that bind Mg and prevent its absorption in the gut (17). SBS itself can cause diarrhea, but sometimes Mg supplementation increases intestinal motility, leading to further diarrhea, which in turn increases the loss of water and electrolytes and leads to secondary hyperaldosteronism and further renal Mg wasting (18). Familial hypomagnesemia with hypercalciuria and nephrocalcinosis, a rare autosomal recessive disorder, is characterized by severe renal Mg and calcium wasting (19). Acute CPP arthritis due to hypomagnesemia has also been described in patients with liver transplant, in whom it has been suspected to occur from a combination of Mg depletion before transplant and tacrolimus use, which induces renal Mg leakage (20). The relationship between hyperparathyroidism and hypomagnesemia is complex. Hyperparathyroidism is an independent risk factor for CPPD disease. However, extreme hypomagnesemia immediately after parathyroidectomy and precipitation of acute CPP arthritis in this setting have also been described (21). It has been proposed that hypomagnesemia in the period after parathyroidectomy for hyperparathyroidism is related to the hungry bone syndrome and Mg being driven from the extracellular to the intracellular space (22).

Management

Treatment of the underlying disorder, correction of hypomagnesemia, and treatment of joint inflammation (with NSAIDs, prednisone or colchicine) were simultaneously used in most of the patients described. Both Bartter and Gitelman syndrome are treated with medications that block the distal tubule sodium-potassium exchange. In addition, NSAIDs are also

administered for Bartter syndrome, in which renal prostaglandin E2 (PGE2) is often markedly increased. Potassium and Mg replacement should be performed for both Gitelman and Bartter syndromes. In a 6-month duration double-blinded placebo-controlled trial, Doherty et al. (23) reported improvement in symptoms of CPPD in patients treated with Mg.

The main reason for hypomagnesemia in SBS is primarily malabsorption due to various factors previously described (18, 24). The mainstay of therapy therefore constitutes replacement therapy, often requiring parenteral supplementation in severe cases, followed by long-term oral supplementation. In patients with diuretic-induced hypomagnesemia, apart from replacing Mg, switching to a different form of therapy or diuretic should be considered. In patients with hyperparathyroidism, undergoing parathyroidectomy treatment with parenteral Mg replacements to prevent acute CPP arthritis in the post-surgery period should be attempted (22, 25).

Besides the treatment of the underlying disorder causing hypomagnesemia and appropriate Mg replacement, the treatment of inflammatory arthritis should be pursued as in any other crystal arthritides. Acute CPP arthritis can be treated with intra-articular or oral steroids, colchicine, or NSAIDs. Treatment of chronic CPP arthritis can be challenging and mainly consists of periodic intra-articular steroid injections for mono or oligoarthritis, colchicine 0.6-1.2 mg daily, daily NSAIDs, low-dose oral prednisone, or any combination of these. Treatment with interleukin-1 β inhibitors, albeit very expensive, is also an option in the management of CPP arthritis (26). Hydroxychloroquine has been described in chronic CPP arthritis to have some benefits (27). The efficacy of methotrexate in chronic CPP arthritis is controversial; however, it is a reasonable option in patients who fail the standard treatment options (28, 29).

Conclusion

Hypomagnesemia is a rare but treatable cause of CPPD disease. Magnesium levels should be measured as part of diagnostic work-up of CPPD disease, especially in younger patients.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - A.J., C.S.; Design - A.J., C.S.; Supervision - A.J., C.S.; Resources - A.J., C.S.; Materials - A.J., C.S.; Data Collection and/or Processing - A.J., C.S.; Analysis and/or Interpretation - A.J., C.S.; Literature Search - A.J., C.S.; Writing Manuscript - A.J., C.S.; Critical Review - C.S.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

References

- Mandl F. Zur pathologie und therapie der zwischenknorpelerkrankungen des kniegelenkes. *Arch Klin Chir* 1927; 146: 149-214.
- Žitňan D, Sit'aj Š. Chondrocalcinosis Articularis. *Ann Rheum Dis* 1963; 22: 142-52. [\[CrossRef\]](#)
- Mccarty DJ, Kohn NN, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: The "Pseudogout Syndrome": I. Clinical Aspects. *Ann Intern Med* 1962; 56: 711. [\[CrossRef\]](#)
- McCarty DJ. Calcium pyrophosphate dihydrate crystal deposition disease: nomenclature and diagnostic criteria. *Ann Intern Med* 1977; 87: 241-2. [\[CrossRef\]](#)
- Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. *Ann Rheum Dis* 2011; 70: 563-70. [\[CrossRef\]](#)
- Punzi L, Oliviero F, Ramonda R. Transforming growth factor-beta levels in synovial fluid of osteoarthritis with or without calcium pyrophosphate dihydrate crystals. *J Rheumatol* 2003; 30: 420-1.
- Rosenthal AK, Cheung HS, Ryan LM. Transforming growth factor beta 1 stimulates inorganic pyrophosphate elaboration by porcine cartilage. *Arthritis Rheum* 1991; 34: 904-11. [\[CrossRef\]](#)
- Olmez U, Ryan LM, Kurup IV, Rosenthal AK. Insulin-like growth factor-1 suppresses pyrophosphate elaboration by transforming growth factor beta1-stimulated chondrocytes and cartilage. *Osteoarthritis Cartilage* 1994; 2: 149-54. [\[CrossRef\]](#)
- Johnson K, Farley D, Hu SI, Terkeltaub R. One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist. *Arthritis Rheum* 2003; 48: 1302-14. [\[CrossRef\]](#)
- Lorenzo P, Bayliss MT, Heinegård D. A novel cartilage protein (CILP) present in the mid-zone of human articular cartilage increases with age. *J Biol Chem* 1998; 273: 23463-8. [\[CrossRef\]](#)
- Doré S, Pelletier JP, DiBattista JA, Tardif G, Brazeau P, Martel-Pelletier J. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation. Possible role of IGF-1-binding proteins. *Arthritis Rheum* 1994; 37: 253-63. [\[CrossRef\]](#)
- Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. *Endocr Rev* 1994; 15: 439-61. [\[CrossRef\]](#)
- Takeuchi K, Kure S, Kato T, Taniyama Y, Takahashi N, Ikeda Y, et al. Association of a mutation in thiazide-sensitive Na-Cl cotransporter with familial Gitelman's syndrome. *J Clin Endocrinol Metab* 1996; 81: 4496-9. [\[CrossRef\]](#)
- Riveira-Munoz E, Chang Q, Godefroid N, Hoenderop JG, Bindels RJ, Dahan K, et al. Tran-

- scriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. *J Am Soc Nephrol* 2007; 18: 1271-83. [\[CrossRef\]](#)
- Bauer FM, Glasson P, Vallotton MB, Courvoisier B. [Bartter's syndrome, chondrocalcinosis and hypomagnesemia]. *Schweiz Med Wochenschr* 1979; 109: 1251-6.
- Punzi L, Calò L, Schiavon F, Pianon M, Rosada M, Todesco S. Chondrocalcinosis is a feature of Gitelman's variant of Bartter's syndrome. A new look at the hypomagnesemia associated with calcium pyrophosphate dihydrate crystal deposition disease. *Rev Rhum Engl Ed* 1998; 65: 571-4.
- Nightingale JM. Management of patients with a short bowel. *World J Gastroenterol* 2001; 7: 741-51. [\[CrossRef\]](#)
- Rude RK. Magnesium deficiency: a cause of heterogeneous disease in humans. *J Bone Miner Res* 1998; 13: 749-58. [\[CrossRef\]](#)
- Praga M, Vara J, González-Parra E, Andrés A, Alamo C, Araque A, et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *Kidney Int* 1995; 47: 1419-25. [\[CrossRef\]](#)
- Perez-Ruiz F, Testillano M, Gastaca MA, Herro-Beites AM. "Pseudoseptic" pseudogout associated with hypomagnesemia in liver transplant patients. *Transplantation* 2001; 71: 696-8. [\[CrossRef\]](#)
- Melvin KE. Articular chondrocalcinosis, hyperparathyroidism and pseudogout: hypomagnesaemic crisis. *Proc R Soc Med* 1966; 59: 595-6.
- Fang L, Tang B, Hou D, Meng M, Xiong M, Yang J. Effect of parathyroid hormone on serum magnesium levels: the neglected relationship in hemodialysis patients with secondary hyperparathyroidism. *Ren Fail* 2016; 38: 50-6. [\[CrossRef\]](#)
- Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. *Ann Rheum Dis* 1983; 42: 106-7. [\[CrossRef\]](#)
- Hahn M, Raitheil M, Hagel A, Biermann T, Manger B. Chronic calcium pyrophosphate crystal inflammatory arthritis induced by extreme hypomagnesemia in short bowel syndrome. *BMC Gastroenterol* 2012; 12: 129. [\[CrossRef\]](#)
- De Bruyne J, Chappel R, Mortier G, Debroe M, Holvoet J. [Bartter's syndrome and chondrocalcinosis]. *J Belge Med Phys Rehabil* 1982; 5: 37-45.
- Ottaviani S, Brunier L, Sibilia J, Maurier F, Ardizzone M, Wendling D, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. *Joint Bone Spine* 2013; 80: 178-82. [\[CrossRef\]](#)
- Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. *Compr Ther* 1997; 23: 327-31.
- Finckh A, Mc Carthy GM, Madigan A, Van Linthoudt D, Weber M, Neto D, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. *Arthritis Res Ther* 2014; 16: 458. [\[CrossRef\]](#)
- Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for

- chronic calcium pyrophosphate deposition disease: an exploratory analysis. *Arthritis Rheum* 2007; 56: 688-92. [\[CrossRef\]](#)
30. Whelan BR, O'Shea F, McCarthy G. Pseudoneuropathic CPPD arthropathy: magnesium matters. *Rheumatology (Oxford)* 2008; 47: 551-2. [\[CrossRef\]](#)
 31. Richette P, Ayoub G, Bardin T, Bouvet S, Orcel P, Badran AM. Hypomagnesemia and chondrocalcinosis in short bowel syndrome. *J Rheumatol* 2005; 32: 2434-6.
 32. Ea HK, Blanchard A, Dougados M, Roux C. Chondrocalcinosis secondary to hypomagnesemia in Gitelman's syndrome. *J Rheumatol* 2005; 32: 1840-2.
 33. González Domínguez J, Escudero Contreras A, Pérez Guijo V, Martínez Sánchez FG, Caracuel Ruiz MÁ, Collantes Estévez E. [Chondrocalcinosis and hypomagnesemia: clinical and radiological progression]. *Reumatol Clin* 2008; 4: 37-9. [\[CrossRef\]](#)
 34. Waitman AD, Koffler M, Kaplinsky N. Bartter's syndrome presenting as pseudomyocardial infarction and pseudogout. *Isr J Med Sci* 1992; 28: 885-7.
 35. Milazzo SC, Ahern MJ, Cleland LG, Henderson DR. Calcium pyrophosphate dihydrate deposition disease and familial hypomagnesemia. *J Rheumatol* 1981; 8: 767-71.
 36. Resnick D, Rausch JM. Hypomagnesemia with chondrocalcinosis. *J Can Assoc Radiol* 1984; 35: 214-6.
 37. Salvarani C, Rossi F, Macchioni PL, Baricchi R, Capozzoli N, Castellani S, et al. Bartter's syndrome and chondrocalcinosis: a possible role for hypomagnesemia in the deposition of calcium pyrophosphate dihydrate (CPPD) crystals. *Clin Exp Rheumatol* 1989; 7: 415-20.
 38. Bauer FM, Glasson P, Vallotton MB, Courvoisier B. [Bartter's syndrome, chondrocalcinosis and hypomagnesemia]. *Schweiz Med Wochenschr* 1979; 109: 1251-6.
 39. Goulon M, Raphael JC, De Rohan P. [A fortuitousness association: Bartter's syndrome and chondrocalcinosis (author's transl)]. *Nouv Presse Med* 1980; 9: 1291-5.
 40. Hurault de Ligny B, Baumelou A, Bardin T, Buyse N, Mehaut M. [Chondrocalcinosis during Bartter's syndrome]. *Nouv Presse Med* 1981; 10: 107.
 41. Schwarz HA, Weidmann P, Messerli FH, Zia PK, Flammer J, Reubi RC. [Increased renal prostaglandin E2 secretion in Bartter's syndrome]. *Schweiz Med Wochenschr* 1977; 107: 1870-2.
 42. Punzi L, Calò L, Schiavon F, Pianon M, Rosada M, Todesco S. Chondrocalcinosis is a feature of Gitelman's variant of Bartter's syndrome. A new look at the hypomagnesemia associated with calcium pyrophosphate dihydrate crystal deposition disease. *Rev Rhum Engl Ed* 1998; 65: 571-4.
 43. Cimбек EA, Şen Y, Yuca SA, Peru H. Chondrocalcinosis related to familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Pediatr Endocrinol Metab* 2015; 28: 713-6. [\[CrossRef\]](#)
 44. Hisakawa N, Yasuoka N, Itoh H, Takao T, Jinnouchi C, Nishiya K, et al. A case of Gitelman's syndrome with chondrocalcinosis. *Endocr J* 1998; 45: 261-7. [\[CrossRef\]](#)
 45. Mayoux-Benhamou MA, Clerc D, Ganeval D, Pertuiset N, Massias P. [Articular chondrocalcinosis and hypomagnesemia of renal origin. Apropos of 2 cases]. *Rev Rhum Mal Osteoartic* 1985; 52: 545-8.
 46. Dupond JL, Humbert P, de Wazières B, Wolf JP. [Bartter's syndrome, diffuse articular chondrocalcinosis and nephrogenic hypomagnesemia in an adult]. *Rev Med Interne* 1989; 10: 261-4. [\[CrossRef\]](#)
 47. de Heide LJ, Birkenhäger JC. Bartter's syndrome, hypomagnesaemia and chondrocalcinosis. *Neth J Med* 1991; 39: 148-52.
 48. Jones AC, Chuck AJ, Arie EA, Green DJ, Doherty M. Diseases associated with calcium pyrophosphate deposition disease. *Semin Arthritis Rheum* 1992; 22: 188-202. [\[CrossRef\]](#)
 49. Smilde TJ, Haverman JF, Schipper P, Hermus AR, van Liebergen FJ, Jansen JL, et al. Familial hypokalemia/hypomagnesemia and chondrocalcinosis. *J Rheumatol* 1994; 21: 1515-9.
 50. Muñoz-Fernández S, Pantoja L, Martín Mola E, de Miguel E, Gijón Ba-os J. Chondrocalcinosis associated with Bartter's syndrome and hypomagnesemia. *J Rheumatol* 1994; 21: 1782-3.
 51. Nightingale JM. Management of patients with a short bowel. *World J Gastroenterol* 2001; 7: 741-51. [\[CrossRef\]](#)